JP2015514439A - 大きい標的化ベクターによるヌクレアーゼ媒介標的化 - Google Patents
大きい標的化ベクターによるヌクレアーゼ媒介標的化 Download PDFInfo
- Publication number
- JP2015514439A JP2015514439A JP2015509128A JP2015509128A JP2015514439A JP 2015514439 A JP2015514439 A JP 2015514439A JP 2015509128 A JP2015509128 A JP 2015509128A JP 2015509128 A JP2015509128 A JP 2015509128A JP 2015514439 A JP2015514439 A JP 2015514439A
- Authority
- JP
- Japan
- Prior art keywords
- nucleic acid
- acid sequence
- human
- sequence
- nuclease
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
- 101710163270 Nuclease Proteins 0.000 title claims abstract description 127
- 230000008685 targeting Effects 0.000 title claims description 81
- 239000013598 vector Substances 0.000 title claims description 47
- 230000001404 mediated effect Effects 0.000 title description 3
- 238000000034 method Methods 0.000 claims abstract description 101
- 210000001236 prokaryotic cell Anatomy 0.000 claims abstract description 42
- 230000005783 single-strand break Effects 0.000 claims abstract description 16
- 230000006801 homologous recombination Effects 0.000 claims abstract description 15
- 238000002744 homologous recombination Methods 0.000 claims abstract description 15
- 150000007523 nucleic acids Chemical class 0.000 claims description 491
- 108020004707 nucleic acids Proteins 0.000 claims description 263
- 102000039446 nucleic acids Human genes 0.000 claims description 263
- 108091028043 Nucleic acid sequence Proteins 0.000 claims description 225
- 210000004027 cell Anatomy 0.000 claims description 134
- 238000011144 upstream manufacturing Methods 0.000 claims description 120
- 108700028369 Alleles Proteins 0.000 claims description 118
- 108090000623 proteins and genes Proteins 0.000 claims description 76
- 239000003795 chemical substances by application Substances 0.000 claims description 63
- 201000010099 disease Diseases 0.000 claims description 51
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 claims description 51
- 108700008625 Reporter Genes Proteins 0.000 claims description 42
- 102000006496 Immunoglobulin Heavy Chains Human genes 0.000 claims description 39
- 108010019476 Immunoglobulin Heavy Chains Proteins 0.000 claims description 39
- 108010017070 Zinc Finger Nucleases Proteins 0.000 claims description 38
- 238000012217 deletion Methods 0.000 claims description 36
- 230000037430 deletion Effects 0.000 claims description 36
- 210000004962 mammalian cell Anatomy 0.000 claims description 35
- 230000001105 regulatory effect Effects 0.000 claims description 35
- 102000018120 Recombinases Human genes 0.000 claims description 20
- 108010091086 Recombinases Proteins 0.000 claims description 20
- 230000004048 modification Effects 0.000 claims description 18
- 238000012986 modification Methods 0.000 claims description 18
- 241000283984 Rodentia Species 0.000 claims description 15
- 101000998953 Homo sapiens Immunoglobulin heavy variable 1-2 Proteins 0.000 claims description 13
- 102100036887 Immunoglobulin heavy variable 1-2 Human genes 0.000 claims description 13
- 238000003556 assay Methods 0.000 claims description 11
- 210000002950 fibroblast Anatomy 0.000 claims description 11
- 230000010354 integration Effects 0.000 claims description 9
- 108010065825 Immunoglobulin Light Chains Proteins 0.000 claims description 8
- 102000013463 Immunoglobulin Light Chains Human genes 0.000 claims description 8
- 238000003776 cleavage reaction Methods 0.000 claims description 8
- 210000005260 human cell Anatomy 0.000 claims description 8
- 230000007017 scission Effects 0.000 claims description 8
- 241000124008 Mammalia Species 0.000 claims description 7
- 210000003958 hematopoietic stem cell Anatomy 0.000 claims description 7
- 230000035772 mutation Effects 0.000 claims description 7
- 210000001178 neural stem cell Anatomy 0.000 claims description 7
- 241000588724 Escherichia coli Species 0.000 claims description 6
- 230000001580 bacterial effect Effects 0.000 claims description 5
- 239000012636 effector Substances 0.000 claims description 5
- 239000003623 enhancer Substances 0.000 claims description 5
- 108020004999 messenger RNA Proteins 0.000 claims description 5
- 230000002103 transcriptional effect Effects 0.000 claims description 5
- 241000699800 Cricetinae Species 0.000 claims description 4
- 241000894007 species Species 0.000 claims description 3
- 238000012239 gene modification Methods 0.000 abstract description 31
- 230000005017 genetic modification Effects 0.000 abstract description 31
- 235000013617 genetically modified food Nutrition 0.000 abstract description 31
- 210000003527 eukaryotic cell Anatomy 0.000 abstract description 20
- 230000005782 double-strand break Effects 0.000 abstract description 18
- 239000000203 mixture Substances 0.000 abstract description 14
- 241000699666 Mus <mouse, genus> Species 0.000 description 52
- 102000004169 proteins and genes Human genes 0.000 description 37
- 230000006798 recombination Effects 0.000 description 24
- 238000005215 recombination Methods 0.000 description 24
- 230000004568 DNA-binding Effects 0.000 description 23
- 239000002773 nucleotide Substances 0.000 description 23
- 125000003729 nucleotide group Chemical group 0.000 description 23
- LRFVTYWOQMYALW-UHFFFAOYSA-N 9H-xanthine Chemical compound O=C1NC(=O)NC2=C1NC=N2 LRFVTYWOQMYALW-UHFFFAOYSA-N 0.000 description 16
- 108091026890 Coding region Proteins 0.000 description 16
- 241000700159 Rattus Species 0.000 description 16
- 230000000692 anti-sense effect Effects 0.000 description 16
- 239000003550 marker Substances 0.000 description 16
- -1 IL-14 Proteins 0.000 description 13
- 210000004436 artificial bacterial chromosome Anatomy 0.000 description 13
- 102000004127 Cytokines Human genes 0.000 description 12
- 108090000695 Cytokines Proteins 0.000 description 12
- 108020004414 DNA Proteins 0.000 description 12
- 102000015696 Interleukins Human genes 0.000 description 12
- 108010063738 Interleukins Proteins 0.000 description 12
- 102000002467 interleukin receptors Human genes 0.000 description 12
- 108010093036 interleukin receptors Proteins 0.000 description 12
- 206010028980 Neoplasm Diseases 0.000 description 10
- HCHKCACWOHOZIP-UHFFFAOYSA-N Zinc Chemical compound [Zn] HCHKCACWOHOZIP-UHFFFAOYSA-N 0.000 description 10
- 201000011510 cancer Diseases 0.000 description 10
- 108010082025 cyan fluorescent protein Proteins 0.000 description 10
- 239000012634 fragment Substances 0.000 description 10
- 239000011701 zinc Substances 0.000 description 10
- 229910052725 zinc Inorganic materials 0.000 description 10
- 230000027455 binding Effects 0.000 description 9
- 102000005962 receptors Human genes 0.000 description 9
- 108020003175 receptors Proteins 0.000 description 9
- 102100036475 Alanine aminotransferase 1 Human genes 0.000 description 8
- 108010045123 Blasticidin-S deaminase Proteins 0.000 description 8
- 101001091269 Escherichia coli Hygromycin-B 4-O-kinase Proteins 0.000 description 8
- 108010091358 Hypoxanthine Phosphoribosyltransferase Proteins 0.000 description 8
- 102000018251 Hypoxanthine Phosphoribosyltransferase Human genes 0.000 description 8
- 108010025815 Kanamycin Kinase Proteins 0.000 description 8
- 241000699670 Mus sp. Species 0.000 description 8
- 241000700584 Simplexvirus Species 0.000 description 8
- 101001091268 Streptomyces hygroscopicus Hygromycin-B 7''-O-kinase Proteins 0.000 description 8
- 102000006601 Thymidine Kinase Human genes 0.000 description 8
- 108020004440 Thymidine kinase Proteins 0.000 description 8
- 108010027570 Xanthine phosphoribosyltransferase Proteins 0.000 description 8
- 108010021843 fluorescent protein 583 Proteins 0.000 description 8
- 230000001939 inductive effect Effects 0.000 description 8
- 108010045647 puromycin N-acetyltransferase Proteins 0.000 description 8
- 229940075420 xanthine Drugs 0.000 description 8
- 108090000144 Human Proteins Proteins 0.000 description 7
- 102000003839 Human Proteins Human genes 0.000 description 7
- 108010073062 Transcription Activator-Like Effectors Proteins 0.000 description 7
- 150000001413 amino acids Chemical group 0.000 description 7
- 238000003780 insertion Methods 0.000 description 7
- 230000037431 insertion Effects 0.000 description 7
- 108700028146 Genetic Enhancer Elements Proteins 0.000 description 6
- 108010002350 Interleukin-2 Proteins 0.000 description 6
- 102000000588 Interleukin-2 Human genes 0.000 description 6
- 102100030703 Interleukin-22 Human genes 0.000 description 6
- 102000018697 Membrane Proteins Human genes 0.000 description 6
- 108010052285 Membrane Proteins Proteins 0.000 description 6
- 102000011931 Nucleoproteins Human genes 0.000 description 6
- 108010061100 Nucleoproteins Proteins 0.000 description 6
- 108060008682 Tumor Necrosis Factor Proteins 0.000 description 6
- 210000001185 bone marrow Anatomy 0.000 description 6
- 102000003675 cytokine receptors Human genes 0.000 description 6
- 108010057085 cytokine receptors Proteins 0.000 description 6
- 229940079593 drug Drugs 0.000 description 6
- 239000003814 drug Substances 0.000 description 6
- 239000003446 ligand Substances 0.000 description 6
- 239000000178 monomer Substances 0.000 description 6
- 230000035945 sensitivity Effects 0.000 description 6
- 210000000130 stem cell Anatomy 0.000 description 6
- 210000001519 tissue Anatomy 0.000 description 6
- 102000003390 tumor necrosis factor Human genes 0.000 description 6
- YMHOBZXQZVXHBM-UHFFFAOYSA-N 2,5-dimethoxy-4-bromophenethylamine Chemical compound COC1=CC(CCN)=C(OC)C=C1Br YMHOBZXQZVXHBM-UHFFFAOYSA-N 0.000 description 5
- 102000002260 Alkaline Phosphatase Human genes 0.000 description 5
- 108020004774 Alkaline Phosphatase Proteins 0.000 description 5
- 108091005944 Cerulean Proteins 0.000 description 5
- 241000579895 Chlorostilbon Species 0.000 description 5
- 108091005943 CyPet Proteins 0.000 description 5
- 108010042407 Endonucleases Proteins 0.000 description 5
- 102000004533 Endonucleases Human genes 0.000 description 5
- 108010043121 Green Fluorescent Proteins Proteins 0.000 description 5
- 102000004144 Green Fluorescent Proteins Human genes 0.000 description 5
- 108060001084 Luciferase Proteins 0.000 description 5
- 239000005089 Luciferase Substances 0.000 description 5
- 241000545067 Venus Species 0.000 description 5
- 230000004913 activation Effects 0.000 description 5
- 238000007796 conventional method Methods 0.000 description 5
- 229910052876 emerald Inorganic materials 0.000 description 5
- 239000010976 emerald Substances 0.000 description 5
- 239000005090 green fluorescent protein Substances 0.000 description 5
- 210000001161 mammalian embryo Anatomy 0.000 description 5
- 108010054624 red fluorescent protein Proteins 0.000 description 5
- 229910052594 sapphire Inorganic materials 0.000 description 5
- 239000010980 sapphire Substances 0.000 description 5
- 238000006467 substitution reaction Methods 0.000 description 5
- 238000013518 transcription Methods 0.000 description 5
- 230000035897 transcription Effects 0.000 description 5
- 108091005957 yellow fluorescent proteins Proteins 0.000 description 5
- 208000019838 Blood disease Diseases 0.000 description 4
- 208000024172 Cardiovascular disease Diseases 0.000 description 4
- 102000010789 Interleukin-2 Receptors Human genes 0.000 description 4
- 108010038453 Interleukin-2 Receptors Proteins 0.000 description 4
- 108091092195 Intron Proteins 0.000 description 4
- 208000029578 Muscle disease Diseases 0.000 description 4
- 208000012902 Nervous system disease Diseases 0.000 description 4
- 208000025966 Neurological disease Diseases 0.000 description 4
- 108700026244 Open Reading Frames Proteins 0.000 description 4
- 238000004520 electroporation Methods 0.000 description 4
- 108010026638 endodeoxyribonuclease FokI Proteins 0.000 description 4
- 108020001507 fusion proteins Proteins 0.000 description 4
- 102000037865 fusion proteins Human genes 0.000 description 4
- 210000004602 germ cell Anatomy 0.000 description 4
- 208000014951 hematologic disease Diseases 0.000 description 4
- 208000018706 hematopoietic system disease Diseases 0.000 description 4
- 208000026278 immune system disease Diseases 0.000 description 4
- 208000017169 kidney disease Diseases 0.000 description 4
- 230000004807 localization Effects 0.000 description 4
- 239000000523 sample Substances 0.000 description 4
- 101150061877 Asic1 gene Proteins 0.000 description 3
- 108010012236 Chemokines Proteins 0.000 description 3
- 102000019034 Chemokines Human genes 0.000 description 3
- 102000053602 DNA Human genes 0.000 description 3
- 108050001049 Extracellular proteins Proteins 0.000 description 3
- 101001008255 Homo sapiens Immunoglobulin kappa variable 1D-8 Proteins 0.000 description 3
- 101001047628 Homo sapiens Immunoglobulin kappa variable 2-29 Proteins 0.000 description 3
- 101001008321 Homo sapiens Immunoglobulin kappa variable 2D-26 Proteins 0.000 description 3
- 101001047619 Homo sapiens Immunoglobulin kappa variable 3-20 Proteins 0.000 description 3
- 101001008263 Homo sapiens Immunoglobulin kappa variable 3D-15 Proteins 0.000 description 3
- 101001002470 Homo sapiens Interferon lambda-1 Proteins 0.000 description 3
- 101000853002 Homo sapiens Interleukin-25 Proteins 0.000 description 3
- 101000853000 Homo sapiens Interleukin-26 Proteins 0.000 description 3
- 101000998139 Homo sapiens Interleukin-32 Proteins 0.000 description 3
- 101001043594 Homo sapiens Low-density lipoprotein receptor-related protein 5 Proteins 0.000 description 3
- 101001128431 Homo sapiens Myeloid-derived growth factor Proteins 0.000 description 3
- 101001123448 Homo sapiens Prolactin receptor Proteins 0.000 description 3
- 101000669447 Homo sapiens Toll-like receptor 4 Proteins 0.000 description 3
- 101000764872 Homo sapiens Transient receptor potential cation channel subfamily A member 1 Proteins 0.000 description 3
- 108060003951 Immunoglobulin Proteins 0.000 description 3
- 102100022964 Immunoglobulin kappa variable 3-20 Human genes 0.000 description 3
- 108010002352 Interleukin-1 Proteins 0.000 description 3
- 102000000589 Interleukin-1 Human genes 0.000 description 3
- 108090000174 Interleukin-10 Proteins 0.000 description 3
- 102000003814 Interleukin-10 Human genes 0.000 description 3
- 108090000177 Interleukin-11 Proteins 0.000 description 3
- 102000003815 Interleukin-11 Human genes 0.000 description 3
- 108010065805 Interleukin-12 Proteins 0.000 description 3
- 108090000176 Interleukin-13 Proteins 0.000 description 3
- 102000003812 Interleukin-15 Human genes 0.000 description 3
- 108090000172 Interleukin-15 Proteins 0.000 description 3
- 102000049772 Interleukin-16 Human genes 0.000 description 3
- 101800003050 Interleukin-16 Proteins 0.000 description 3
- 102000013691 Interleukin-17 Human genes 0.000 description 3
- 108050003558 Interleukin-17 Proteins 0.000 description 3
- 102000003810 Interleukin-18 Human genes 0.000 description 3
- 108090000171 Interleukin-18 Proteins 0.000 description 3
- 102100039879 Interleukin-19 Human genes 0.000 description 3
- 108050009288 Interleukin-19 Proteins 0.000 description 3
- 102000007351 Interleukin-2 Receptor alpha Subunit Human genes 0.000 description 3
- 108010032774 Interleukin-2 Receptor alpha Subunit Proteins 0.000 description 3
- 102000008193 Interleukin-2 Receptor beta Subunit Human genes 0.000 description 3
- 108010060632 Interleukin-2 Receptor beta Subunit Proteins 0.000 description 3
- 108010066979 Interleukin-27 Proteins 0.000 description 3
- 108010002386 Interleukin-3 Proteins 0.000 description 3
- 101710181613 Interleukin-31 Proteins 0.000 description 3
- 108010067003 Interleukin-33 Proteins 0.000 description 3
- 101710181549 Interleukin-34 Proteins 0.000 description 3
- 108091007973 Interleukin-36 Proteins 0.000 description 3
- 108090000978 Interleukin-4 Proteins 0.000 description 3
- 108010002616 Interleukin-5 Proteins 0.000 description 3
- 108090001005 Interleukin-6 Proteins 0.000 description 3
- 108010002586 Interleukin-7 Proteins 0.000 description 3
- 108090001007 Interleukin-8 Proteins 0.000 description 3
- 108010002335 Interleukin-9 Proteins 0.000 description 3
- 102100021926 Low-density lipoprotein receptor-related protein 5 Human genes 0.000 description 3
- 102100025169 Max-binding protein MNT Human genes 0.000 description 3
- 102000007399 Nuclear hormone receptor Human genes 0.000 description 3
- 108020005497 Nuclear hormone receptor Proteins 0.000 description 3
- 102100029000 Prolactin receptor Human genes 0.000 description 3
- 101710100963 Receptor tyrosine-protein kinase erbB-4 Proteins 0.000 description 3
- 108010052160 Site-specific recombinase Proteins 0.000 description 3
- 102100039360 Toll-like receptor 4 Human genes 0.000 description 3
- 102100026186 Transient receptor potential cation channel subfamily A member 1 Human genes 0.000 description 3
- 210000003719 b-lymphocyte Anatomy 0.000 description 3
- 210000000748 cardiovascular system Anatomy 0.000 description 3
- 230000001086 cytosolic effect Effects 0.000 description 3
- 210000002249 digestive system Anatomy 0.000 description 3
- 210000002257 embryonic structure Anatomy 0.000 description 3
- 210000000750 endocrine system Anatomy 0.000 description 3
- 238000002474 experimental method Methods 0.000 description 3
- 230000004927 fusion Effects 0.000 description 3
- 210000001654 germ layer Anatomy 0.000 description 3
- 210000003297 immature b lymphocyte Anatomy 0.000 description 3
- 102000018358 immunoglobulin Human genes 0.000 description 3
- 102000004114 interleukin 20 Human genes 0.000 description 3
- 108090000681 interleukin 20 Proteins 0.000 description 3
- 108010074108 interleukin-21 Proteins 0.000 description 3
- 108010074109 interleukin-22 Proteins 0.000 description 3
- 108090000237 interleukin-24 Proteins 0.000 description 3
- 210000004324 lymphatic system Anatomy 0.000 description 3
- 239000000463 material Substances 0.000 description 3
- 210000003519 mature b lymphocyte Anatomy 0.000 description 3
- 210000003205 muscle Anatomy 0.000 description 3
- 210000000653 nervous system Anatomy 0.000 description 3
- 108020004017 nuclear receptors Proteins 0.000 description 3
- 238000003753 real-time PCR Methods 0.000 description 3
- 210000004994 reproductive system Anatomy 0.000 description 3
- 210000002345 respiratory system Anatomy 0.000 description 3
- 210000001082 somatic cell Anatomy 0.000 description 3
- 210000004989 spleen cell Anatomy 0.000 description 3
- 108091006107 transcriptional repressors Proteins 0.000 description 3
- 230000002485 urinary effect Effects 0.000 description 3
- GRRNUXAQVGOGFE-UHFFFAOYSA-N Hygromycin-B Natural products OC1C(NC)CC(N)C(O)C1OC1C2OC3(C(C(O)C(O)C(C(N)CO)O3)O)OC2C(O)C(CO)O1 GRRNUXAQVGOGFE-UHFFFAOYSA-N 0.000 description 2
- 101150008942 J gene Proteins 0.000 description 2
- 101150117115 V gene Proteins 0.000 description 2
- 238000004458 analytical method Methods 0.000 description 2
- 238000013459 approach Methods 0.000 description 2
- 210000001106 artificial yeast chromosome Anatomy 0.000 description 2
- 102000023732 binding proteins Human genes 0.000 description 2
- 108091008324 binding proteins Proteins 0.000 description 2
- 230000002759 chromosomal effect Effects 0.000 description 2
- 108010050663 endodeoxyribonuclease CreI Proteins 0.000 description 2
- 238000009396 hybridization Methods 0.000 description 2
- GRRNUXAQVGOGFE-NZSRVPFOSA-N hygromycin B Chemical compound O[C@@H]1[C@@H](NC)C[C@@H](N)[C@H](O)[C@H]1O[C@H]1[C@H]2O[C@@]3([C@@H]([C@@H](O)[C@@H](O)[C@@H](C(N)CO)O3)O)O[C@H]2[C@@H](O)[C@@H](CO)O1 GRRNUXAQVGOGFE-NZSRVPFOSA-N 0.000 description 2
- 229940097277 hygromycin b Drugs 0.000 description 2
- 230000006698 induction Effects 0.000 description 2
- 210000000472 morula Anatomy 0.000 description 2
- 239000013612 plasmid Substances 0.000 description 2
- 238000012207 quantitative assay Methods 0.000 description 2
- 238000012360 testing method Methods 0.000 description 2
- 108091032973 (ribonucleotides)n+m Proteins 0.000 description 1
- FWMNVWWHGCHHJJ-SKKKGAJSSA-N 4-amino-1-[(2r)-6-amino-2-[[(2r)-2-[[(2r)-2-[[(2r)-2-amino-3-phenylpropanoyl]amino]-3-phenylpropanoyl]amino]-4-methylpentanoyl]amino]hexanoyl]piperidine-4-carboxylic acid Chemical compound C([C@H](C(=O)N[C@H](CC(C)C)C(=O)N[C@H](CCCCN)C(=O)N1CCC(N)(CC1)C(O)=O)NC(=O)[C@H](N)CC=1C=CC=CC=1)C1=CC=CC=C1 FWMNVWWHGCHHJJ-SKKKGAJSSA-N 0.000 description 1
- 241000283690 Bos taurus Species 0.000 description 1
- 241000283707 Capra Species 0.000 description 1
- 241000282994 Cervidae Species 0.000 description 1
- 230000004544 DNA amplification Effects 0.000 description 1
- 101100239628 Danio rerio myca gene Proteins 0.000 description 1
- 102000004190 Enzymes Human genes 0.000 description 1
- 108090000790 Enzymes Proteins 0.000 description 1
- 241000282326 Felis catus Species 0.000 description 1
- 241000287828 Gallus gallus Species 0.000 description 1
- 101000854886 Homo sapiens Immunoglobulin iota chain Proteins 0.000 description 1
- 101001139134 Homo sapiens Krueppel-like factor 4 Proteins 0.000 description 1
- 101000984042 Homo sapiens Protein lin-28 homolog A Proteins 0.000 description 1
- 102000017727 Immunoglobulin Variable Region Human genes 0.000 description 1
- 108010067060 Immunoglobulin Variable Region Proteins 0.000 description 1
- 102100020744 Immunoglobulin iota chain Human genes 0.000 description 1
- 102100020677 Krueppel-like factor 4 Human genes 0.000 description 1
- 101150039798 MYC gene Proteins 0.000 description 1
- 241000282560 Macaca mulatta Species 0.000 description 1
- 241001465754 Metazoa Species 0.000 description 1
- 101100179574 Mus musculus Il2rg gene Proteins 0.000 description 1
- 241000282341 Mustela putorius furo Species 0.000 description 1
- 108010021466 Mutant Proteins Proteins 0.000 description 1
- 102000008300 Mutant Proteins Human genes 0.000 description 1
- 241000283973 Oryctolagus cuniculus Species 0.000 description 1
- 241001494479 Pecora Species 0.000 description 1
- 241000288906 Primates Species 0.000 description 1
- 102100025460 Protein lin-28 homolog A Human genes 0.000 description 1
- 101100247004 Rattus norvegicus Qsox1 gene Proteins 0.000 description 1
- 101150086694 SLC22A3 gene Proteins 0.000 description 1
- 108091081021 Sense strand Proteins 0.000 description 1
- 238000002105 Southern blotting Methods 0.000 description 1
- 102000004357 Transferases Human genes 0.000 description 1
- 108090000992 Transferases Proteins 0.000 description 1
- 101100459258 Xenopus laevis myc-a gene Proteins 0.000 description 1
- PYMYPHUHKUWMLA-WDCZJNDASA-N arabinose Chemical compound OC[C@@H](O)[C@@H](O)[C@H](O)C=O PYMYPHUHKUWMLA-WDCZJNDASA-N 0.000 description 1
- PYMYPHUHKUWMLA-UHFFFAOYSA-N arabinose Natural products OCC(O)C(O)C(O)C=O PYMYPHUHKUWMLA-UHFFFAOYSA-N 0.000 description 1
- 230000008901 benefit Effects 0.000 description 1
- SRBFZHDQGSBBOR-UHFFFAOYSA-N beta-D-Pyranose-Lyxose Natural products OC1COC(O)C(O)C1O SRBFZHDQGSBBOR-UHFFFAOYSA-N 0.000 description 1
- 210000002459 blastocyst Anatomy 0.000 description 1
- 125000003178 carboxy group Chemical group [H]OC(*)=O 0.000 description 1
- 238000006243 chemical reaction Methods 0.000 description 1
- 210000000349 chromosome Anatomy 0.000 description 1
- 230000000052 comparative effect Effects 0.000 description 1
- 238000010586 diagram Methods 0.000 description 1
- 210000001671 embryonic stem cell Anatomy 0.000 description 1
- 238000010195 expression analysis Methods 0.000 description 1
- 239000007850 fluorescent dye Substances 0.000 description 1
- 230000004077 genetic alteration Effects 0.000 description 1
- 231100000118 genetic alteration Toxicity 0.000 description 1
- 238000010353 genetic engineering Methods 0.000 description 1
- 230000037442 genomic alteration Effects 0.000 description 1
- 238000003205 genotyping method Methods 0.000 description 1
- 230000012010 growth Effects 0.000 description 1
- 238000007901 in situ hybridization Methods 0.000 description 1
- 238000000338 in vitro Methods 0.000 description 1
- 239000000411 inducer Substances 0.000 description 1
- 241001515942 marmosets Species 0.000 description 1
- 230000006780 non-homologous end joining Effects 0.000 description 1
- 125000002924 primary amino group Chemical group [H]N([H])* 0.000 description 1
- 230000008569 process Effects 0.000 description 1
- 230000001737 promoting effect Effects 0.000 description 1
- 230000022532 regulation of transcription, DNA-dependent Effects 0.000 description 1
- 238000012216 screening Methods 0.000 description 1
- 230000003584 silencer Effects 0.000 description 1
- 239000000758 substrate Substances 0.000 description 1
- 238000010809 targeting technique Methods 0.000 description 1
Images
Classifications
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
- C12N15/09—Recombinant DNA-technology
- C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
- C12N15/79—Vectors or expression systems specially adapted for eukaryotic hosts
- C12N15/85—Vectors or expression systems specially adapted for eukaryotic hosts for animal cells
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
- C07K14/715—Receptors; Cell surface antigens; Cell surface determinants for cytokines; for lymphokines; for interferons
- C07K14/7155—Receptors; Cell surface antigens; Cell surface determinants for cytokines; for lymphokines; for interferons for interleukins [IL]
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
- C12N15/09—Recombinant DNA-technology
- C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
- C12N15/79—Vectors or expression systems specially adapted for eukaryotic hosts
- C12N15/85—Vectors or expression systems specially adapted for eukaryotic hosts for animal cells
- C12N15/8509—Vectors or expression systems specially adapted for eukaryotic hosts for animal cells for producing genetically modified animals, e.g. transgenic
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
- C12N15/09—Recombinant DNA-technology
- C12N15/87—Introduction of foreign genetic material using processes not otherwise provided for, e.g. co-transformation
- C12N15/90—Stable introduction of foreign DNA into chromosome
- C12N15/902—Stable introduction of foreign DNA into chromosome using homologous recombination
- C12N15/907—Stable introduction of foreign DNA into chromosome using homologous recombination in mammalian cells
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Genetics & Genomics (AREA)
- Chemical & Material Sciences (AREA)
- Engineering & Computer Science (AREA)
- Organic Chemistry (AREA)
- Zoology (AREA)
- Biomedical Technology (AREA)
- Biotechnology (AREA)
- General Engineering & Computer Science (AREA)
- Wood Science & Technology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Molecular Biology (AREA)
- Biophysics (AREA)
- Biochemistry (AREA)
- General Health & Medical Sciences (AREA)
- Plant Pathology (AREA)
- Physics & Mathematics (AREA)
- Microbiology (AREA)
- Cell Biology (AREA)
- Immunology (AREA)
- Mycology (AREA)
- Veterinary Medicine (AREA)
- Toxicology (AREA)
- Gastroenterology & Hepatology (AREA)
- Medicinal Chemistry (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Micro-Organisms Or Cultivation Processes Thereof (AREA)
- Enzymes And Modification Thereof (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Abstract
Description
(a)哺乳動物の標的ゲノム遺伝子座を含む原核細胞中に、以下:
(i)第1の上流相同性アームおよび第1の下流相同性アームに隣接したインサート核酸を含む標的化ベクター、および
(ii)標的ゲノム遺伝子座またはその近傍において一本鎖切断または二本鎖切断を作製するヌクレアーゼ剤、
を導入するステップ、ならびに
(b)インサート核酸を含む標的化された原核細胞を選択するステップ、
を含み、
この原核細胞は、BHRを媒介するリコンビナーゼを発現することが可能である。
定義
(実施例1)
ジンクフィンガーヌクレアーゼ(ZFN)により増強されたLTVECの標的化
Claims (64)
- 哺乳動物細胞において標的ゲノム遺伝子座を改変する方法であって、
(a)哺乳動物細胞中に、以下:
(i)標的ゲノム遺伝子座またはその近傍において一本鎖切断または二本鎖切断を作製するヌクレアーゼ剤、および
(ii)上流相同性アームおよび下流相同性アームに隣接したインサート核酸を含む大きい標的化ベクター(LTVEC)、
を導入するステップ;ならびに
(b)該標的ゲノム遺伝子座中に前記インサート核酸を含む標的化された哺乳動物細胞を選択するステップ、
を含む、方法。 - 前記哺乳動物細胞が多能性細胞である、請求項1に記載の方法。
- 前記哺乳動物細胞が誘導多能性幹(iPS)細胞である、請求項1に記載の方法。
- 前記多能性細胞がマウス胚性幹(ES)細胞である、請求項2に記載の方法。
- 前記多能性細胞が造血幹細胞である、請求項2に記載の方法。
- 前記多能性細胞が神経幹細胞である、請求項2に記載の方法。
- 前記哺乳動物細胞がヒト線維芽細胞である、請求項1に記載の方法。
- 前記哺乳動物細胞が、疾患を有する患者から単離されたヒト細胞であり、該ヒト細胞が、そのゲノム中に少なくとも1つのヒト疾患対立遺伝子を含む、請求項1に記載の方法。
- 前記標的ゲノム遺伝子座中への前記インサート核酸の組込みが、前記ゲノム中の前記少なくとも1つのヒト疾患対立遺伝子を置換する、請求項8に記載の方法。
- 前記LTVECと前記ヌクレアーゼ剤との併用が、前記LTVEC単独の使用と比較して、増加した標的化効率を生じさせる、請求項1に記載の方法。
- 前記LTVECの前記標的化効率が、前記LTVEC単独の使用と比較して、少なくとも2倍増加される、請求項10に記載の方法。
- 前記ヌクレアーゼ剤が、ヌクレアーゼをコードする核酸配列を含む発現構築物であり、前記核酸が、前記哺乳動物細胞において活性なプロモーターに作動可能に連結している、請求項1に記載の方法。
- 前記ヌクレアーゼ剤が、ヌクレアーゼをコードするmRNAである、請求項1に記載の方法。
- 前記ヌクレアーゼがジンクフィンガーヌクレアーゼ(ZFN)である、請求項12に記載の方法。
- 前記ヌクレアーゼが転写アクチベータ様エフェクターヌクレアーゼ(TALEN)である、請求項12に記載の方法。
- 前記ヌクレアーゼがメガヌクレアーゼである、請求項12に記載の方法。
- 前記ヌクレアーゼ剤の標的配列が、前記標的ゲノム遺伝子座中のイントロン、エクソン、プロモーター、プロモーター調節領域またはエンハンサー領域中に位置付けられる、請求項1に記載の方法。
- 前記上流相同性アームおよび前記下流相同性アームの総計が少なくとも10kbである、請求項1に記載の方法。
- 前記インサート核酸が、約5kbから300kbまでの範囲の長さである、請求項1に記載の方法。
- 前記インサート核酸が選択カセットを含む、請求項1に記載の方法。
- 前記インサート核酸がレポーター遺伝子を含む、請求項1に記載の方法。
- 前記標的ゲノム遺伝子座中への前記インサート核酸の組込みが、前記標的ゲノム遺伝子座における内因性遺伝子の欠失を生じさせる、請求項1に記載の方法。
- 前記標的ゲノム遺伝子座中への前記インサート核酸の組込みが、前記標的ゲノム遺伝子座における外因性配列の付加を生じさせる、請求項1に記載の方法。
- 前記標的ゲノム遺伝子座中への前記インサート核酸の組込みが、ノックアウト、ノックイン、点変異、ドメインスワップ、エクソンスワップ、イントロンスワップ、調節配列スワップ、遺伝子スワップまたはそれらの組合せを生じさせる、請求項1に記載の方法。
- 前記インサート核酸が、ヒト核酸配列を含む、請求項1に記載の方法。
- 前記インサート核酸が、免疫グロブリン重鎖定常領域核酸配列に作動可能に連結した再編成されていないヒト免疫グロブリン重鎖可変領域核酸配列を含む、請求項25に記載の方法。
- 前記免疫グロブリン重鎖定常領域配列が、マウス免疫グロブリン重鎖定常領域配列、ヒト免疫グロブリン重鎖定常領域配列またはそれらの組合せである、請求項26に記載の方法。
- 前記免疫グロブリン重鎖定常領域核酸配列が、CH1、ヒンジ、CH2、CH3およびそれらの組合せから選択される、請求項26に記載の方法。
- 前記インサート核酸が、λ軽鎖定常領域核酸配列およびκ軽鎖定常領域核酸配列から選択されるマウスまたはヒトの免疫グロブリン軽鎖定常領域核酸配列に作動可能に連結した再編成されていないヒトλまたはκ軽鎖可変領域核酸配列を含む、請求項1に記載の方法。
- 前記インサート核酸が、λ軽鎖定常領域核酸配列およびκ軽鎖定常領域核酸配列から選択されるマウスまたはヒトの免疫グロブリン軽鎖定常領域核酸配列に作動可能に連結した再編成されたヒトλまたはκ軽鎖可変領域核酸配列を含む、請求項1に記載の方法。
- 選択するステップ(b)が、対立遺伝子の改変(MOA)アッセイを介して実行される、請求項1に記載の方法。
- 前記インサート核酸が、前記哺乳動物細胞のゲノム中の核酸配列に対して相同な核酸配列を含む、請求項1に記載の方法。
- 前記インサート核酸が、前記哺乳動物細胞のゲノム中の核酸配列に対してオルソロガスな核酸配列を含む、請求項1に記載の方法。
- 前記インサート核酸が、異なる種由来の核酸配列を含む、請求項1に記載の方法。
- 前記標的化された哺乳動物細胞が、そのゲノム中に、約5kbから約300kbまでの範囲の前記インサート核酸を含む、請求項1に記載の方法。
- 原核細胞において細菌相同組換え(BHR)を介して哺乳動物の標的ゲノム遺伝子座を改変する方法であって、
(a)哺乳動物の標的ゲノム遺伝子座を含む原核細胞中に、以下:
(i)第1の上流相同性アームおよび第1の下流相同性アームに隣接したインサート核酸を含む標的化ベクター、および
(ii)前記標的ゲノム遺伝子座またはその近傍において一本鎖切断または二本鎖切断を作製するヌクレアーゼ剤、
を導入するステップ、ならびに
(b)前記インサート核酸を含む標的化された原核細胞を選択するステップ、
を含み、
ここで、前記標的ゲノム遺伝子座は、第2の上流相同性アームおよび第2の下流相同性アームを含む大きい標的化ベクター(LTVEC)中に存在し、
前記原核細胞が、前記BHRを媒介するリコンビナーゼを発現することが可能である、方法。 - 前記哺乳動物がヒトである、請求項36に記載の方法。
- 前記哺乳動物がげっ歯類である、請求項36に記載の方法。
- 前記げっ歯類が、マウス、ラットまたはハムスターである、請求項38に記載の方法。
- 前記標的化ベクターと前記ヌクレアーゼ剤との併用が、前記標的化ベクター単独の使用と比較して、増加した標的化効率を生じさせる、請求項36に記載の方法。
- 前記標的化効率が、前記標的化ベクター単独の使用と比較して、少なくとも2倍増加される、請求項40に記載の方法。
- 前記原核細胞が、組換えコンピテント株のE.coliである、請求項36に記載の方法。
- 前記原核細胞が、前記リコンビナーゼをコードする核酸を含む、請求項36に記載の方法。
- 前記原核細胞が、前記リコンビナーゼをコードする核酸を含まず、前記リコンビナーゼをコードする該核酸が、前記原核細胞中に導入される、請求項36に記載の方法。
- 前記ヌクレアーゼ剤が、ヌクレアーゼをコードする核酸配列を含む発現構築物であり、該核酸が、前記原核細胞において活性なプロモーターに作動可能に連結している、請求項36に記載の方法。
- 前記ヌクレアーゼ剤が、ヌクレアーゼをコードするmRNAである、請求項36に記載の方法。
- 前記ヌクレアーゼがジンクフィンガーヌクレアーゼ(ZFN)である、請求項45に記載の方法。
- 前記ヌクレアーゼが転写アクチベータ様エフェクターヌクレアーゼ(TALEN)である、請求項45に記載の方法。
- 前記ヌクレアーゼがメガヌクレアーゼである、請求項45に記載の方法。
- 前記ヌクレアーゼ剤の標的配列が、前記標的ゲノム遺伝子座中のイントロン、エクソン、プロモーター、プロモーター調節領域またはエンハンサー領域中に位置付けられる、請求項36に記載の方法。
- 前記第2の上流相同性アームおよび前記第2の下流相同性アームの総計が少なくとも10kbである、請求項36に記載の方法。
- 前記インサート核酸が、約5kbから300kbまでの範囲の長さである、請求項36に記載の方法。
- 前記インサート核酸が選択カセットを含む、請求項36に記載の方法。
- 前記インサート核酸がレポーター遺伝子を含む、請求項36に記載の方法。
- 前記標的ゲノム遺伝子座中への前記インサート核酸の組込みが、前記標的ゲノム遺伝子座における内因性遺伝子の欠失を生じさせる、請求項36に記載の方法。
- 前記標的ゲノム遺伝子座中への前記インサート核酸の組込みが、前記標的ゲノム遺伝子座における外因性配列の付加を生じさせる、請求項36に記載の方法。
- 前記標的ゲノム遺伝子座中への前記インサート核酸の組込みが、ノックアウト、ノックイン、点変異、ドメインスワップ、エクソンスワップ、イントロンスワップ、調節配列スワップ、遺伝子スワップまたはそれらの組合せを生じさせる、請求項36に記載の方法。
- 前記インサート核酸が、ヒト核酸配列である、請求項36に記載の方法。
- 前記インサート核酸が、免疫グロブリン重鎖定常領域核酸配列に作動可能に連結した再編成されていないヒト免疫グロブリン重鎖可変領域核酸配列を含む、請求項58に記載の方法。
- 前記免疫グロブリン重鎖定常領域配列が、マウス免疫グロブリン重鎖定常領域配列、ヒト免疫グロブリン重鎖定常領域配列またはそれらの組合せである、請求項59に記載の方法。
- 前記免疫グロブリン重鎖定常領域核酸配列が、CH1、ヒンジ、CH2、CH3およびそれらの組合せから選択される、請求項59に記載の方法。
- 前記インサート核酸が、λ軽鎖定常領域核酸配列およびκ軽鎖定常領域核酸配列から選択されるマウスまたはヒトの免疫グロブリン軽鎖定常領域核酸配列に作動可能に連結した再編成されていないヒトλまたはκ軽鎖可変領域核酸配列を含む、請求項36に記載の方法。
- 前記インサート核酸が、λ軽鎖定常領域核酸配列およびκ軽鎖定常領域核酸配列から選択されるマウスまたはヒトの免疫グロブリン軽鎖定常領域核酸配列に作動可能に連結した再編成されたヒトλまたはκ軽鎖可変領域核酸配列を含む、請求項36に記載の方法。
- 選択するステップ(b)が、対立遺伝子の改変(MOA)アッセイを介して実行される、請求項36に記載の方法。
Applications Claiming Priority (3)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US201261638267P | 2012-04-25 | 2012-04-25 | |
US61/638,267 | 2012-04-25 | ||
PCT/US2013/038165 WO2013163394A1 (en) | 2012-04-25 | 2013-04-25 | Nuclease-mediated targeting with large targeting vectors |
Publications (3)
Publication Number | Publication Date |
---|---|
JP2015514439A true JP2015514439A (ja) | 2015-05-21 |
JP2015514439A5 JP2015514439A5 (ja) | 2016-06-02 |
JP6275120B2 JP6275120B2 (ja) | 2018-02-07 |
Family
ID=48289700
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
JP2015509128A Active JP6275120B2 (ja) | 2012-04-25 | 2013-04-25 | 大きい標的化ベクターによるヌクレアーゼ媒介標的化 |
Country Status (20)
Country | Link |
---|---|
US (2) | US9834786B2 (ja) |
EP (1) | EP2847335B1 (ja) |
JP (1) | JP6275120B2 (ja) |
KR (1) | KR101904508B1 (ja) |
CN (2) | CN104364380B (ja) |
AU (1) | AU2013251558B2 (ja) |
BR (1) | BR112014026294B1 (ja) |
CA (1) | CA2869016C (ja) |
CY (1) | CY1120572T1 (ja) |
DK (1) | DK2847335T3 (ja) |
ES (1) | ES2683071T3 (ja) |
HK (1) | HK1207396A1 (ja) |
IL (1) | IL234905B (ja) |
IN (1) | IN2014DN09261A (ja) |
MX (1) | MX362523B (ja) |
PL (1) | PL2847335T3 (ja) |
PT (1) | PT2847335T (ja) |
RU (1) | RU2645475C2 (ja) |
SG (2) | SG11201406547YA (ja) |
WO (1) | WO2013163394A1 (ja) |
Families Citing this family (45)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
IN2014DN09261A (ja) | 2012-04-25 | 2015-07-10 | Regeneron Pharma | |
EP4289948A3 (en) | 2012-05-25 | 2024-04-17 | The Regents of the University of California | Methods and compositions for rna-directed target dna modification and for rna-directed modulation of transcription |
US20160017366A1 (en) | 2012-12-06 | 2016-01-21 | Sigma-Aldrich Co. Llc | Crispr-based genome modification and regulation |
BR112015019950B1 (pt) | 2013-02-20 | 2023-02-14 | Regeneron Pharmaceuticals, Inc | Método para gerar linhagem de células-tronco embrionárias (es) de rato, e, cultura in vitro |
HUE040575T2 (hu) | 2013-04-16 | 2019-03-28 | Regeneron Pharma | A patkány genom célzott módosítása |
ES2844174T3 (es) | 2013-09-18 | 2021-07-21 | Kymab Ltd | Métodos, células y organismos |
KR101566498B1 (ko) * | 2013-11-13 | 2015-11-06 | 건국대학교 산학협력단 | 인터루킨 2 수용체 감마 유전자 적중벡터, 그 벡터가 도입된 면역세포 결핍 형질전환 미니 복제돼지 생산과 그 제조방법 및 활용 |
US10787684B2 (en) * | 2013-11-19 | 2020-09-29 | President And Fellows Of Harvard College | Large gene excision and insertion |
AU2014360811B2 (en) | 2013-12-11 | 2017-05-18 | Regeneron Pharmaceuticals, Inc. | Methods and compositions for the targeted modification of a genome |
HUE049776T2 (hu) * | 2014-06-06 | 2020-10-28 | Regeneron Pharma | Módszerek és készítmények egy célzott lókusz módosítására |
ES2901074T3 (es) | 2014-06-26 | 2022-03-21 | Regeneron Pharma | Métodos y composiciones para modificaciones genéticas objetivo y métodos de uso |
DK3207124T3 (da) | 2014-10-15 | 2019-08-12 | Regeneron Pharma | Fremgangsmåder og sammensætninger til generering eller bevaring af pluripotente celler |
SI3221457T1 (sl) | 2014-11-21 | 2019-08-30 | Regeneron Pharmaceuticals, Inc. | Postopki in sestavki za ciljno genetsko modifikacijo z uporabo vodilnih RNK v parih |
AU2015364427B2 (en) | 2014-12-19 | 2021-05-27 | Regeneron Pharmaceuticals, Inc. | Methods and compositions for targeted genetic modification through single-step multiple targeting |
IL274285B (en) | 2015-03-16 | 2022-07-01 | Regeneron Pharma | Non-human animals exhibiting reduced upper and lower motor neuron function and sensory perception |
JP6619822B2 (ja) * | 2015-05-29 | 2019-12-11 | リジェネロン・ファーマシューティカルズ・インコーポレイテッドRegeneron Pharmaceuticals, Inc. | C9orf72遺伝子座における破壊を有する非ヒト動物 |
AU2017336100B2 (en) | 2016-09-30 | 2023-11-30 | Regeneron Pharmaceuticals, Inc. | Non-human animals having a hexanucleotide repeat expansion in a C9ORF72 locus |
CA3066945A1 (en) | 2017-06-27 | 2019-01-03 | Regeneron Pharmaceuticals, Inc. | Non-human animals comprising a humanized asgr1 locus |
BR112020001996A2 (pt) | 2017-07-31 | 2020-08-18 | Regeneron Pharmaceuticals, Inc. | animal não humano, e, métodos para testar e para otimizar a capacidade de uma crispr/cas nuclease de excisar um ácido nucleico genômico in vivo, para testar a recombinação induzida por crispr/cas de um ácido nucleico genômico com um ácido nucleico de doador exógeno in vivo e para otimizar a capacidade de crispr/cas de induzir a recombinação de um ácido nucleico genômico com um ácido nucleico de doador exógeno in vivo. |
SG11201912235PA (en) | 2017-07-31 | 2020-01-30 | Regeneron Pharma | Cas-transgenic mouse embryonic stem cells and mice and uses thereof |
WO2019028029A1 (en) | 2017-07-31 | 2019-02-07 | Regeneron Pharmaceuticals, Inc. | EVALUATION OF CRISPR / CAS INDUCED RECOMBINATION WITH IN VIVO EXOGENIC DONOR NUCLEIC ACID |
CA3071712C (en) | 2017-09-29 | 2023-02-14 | Regeneron Pharmaceuticals, Inc. | Non-human animals comprising a humanized ttr locus and methods of use |
WO2019094735A1 (en) | 2017-11-10 | 2019-05-16 | Regeneron Pharmaceuticals, Inc. | Non-human animals comprising slc30a8 mutation and methods of use |
JP7361031B2 (ja) | 2017-11-30 | 2023-10-13 | リジェネロン・ファーマシューティカルズ・インコーポレイテッド | ヒト化trkb遺伝子座を含む非ヒト動物 |
WO2019183123A1 (en) | 2018-03-19 | 2019-09-26 | Regeneron Pharmaceuticals, Inc. | Transcription modulation in animals using crispr/cas systems |
JP7222075B2 (ja) | 2018-09-13 | 2023-02-14 | リジェネロン・ファーマシューティカルズ・インコーポレイテッド | C3糸球体症のモデルとしての補体因子h遺伝子ノックアウトラット |
WO2020131632A1 (en) | 2018-12-20 | 2020-06-25 | Regeneron Pharmaceuticals, Inc. | Nuclease-mediated repeat expansion |
ES2966625T3 (es) | 2019-04-04 | 2024-04-23 | Regeneron Pharma | Roedores que comprenden un locus del factor de coagulación 12 humanizado |
CA3137761A1 (en) | 2019-06-04 | 2020-12-10 | Regeneron Pharmaceuticals, Inc. | Non-human animals comprising a humanized ttr locus with a beta-slip mutation and methods of use |
CA3137764A1 (en) | 2019-06-07 | 2020-12-10 | Regeneron Pharmaceuticals, Inc. | Non-human animals comprising a humanized albumin locus |
RU2722933C1 (ru) * | 2019-06-11 | 2020-06-05 | Автономная некоммерческая образовательная организация высшего образования Сколковский институт науки и технологий | Средство разрезания днк на основе cas9 белка из бактерии demequina sediminicola |
WO2021108363A1 (en) | 2019-11-25 | 2021-06-03 | Regeneron Pharmaceuticals, Inc. | Crispr/cas-mediated upregulation of humanized ttr allele |
AU2021212668A1 (en) | 2020-01-28 | 2022-08-18 | Regeneron Pharmaceuticals, Inc. | Non-human animals comprising a humanized PNPLA3 locus and methods of use |
US20230081547A1 (en) | 2020-02-07 | 2023-03-16 | Regeneron Pharmaceuticals, Inc. | Non-human animals comprising a humanized klkb1 locus and methods of use |
US20230102342A1 (en) | 2020-03-23 | 2023-03-30 | Regeneron Pharmaceuticals, Inc. | Non-human animals comprising a humanized ttr locus comprising a v30m mutation and methods of use |
EP4171215A2 (en) | 2020-06-26 | 2023-05-03 | Regeneron Pharmaceuticals, Inc. | Non-human animals comprising a humanized ace2 locus |
DE112022001365T5 (de) | 2021-03-05 | 2024-02-15 | The Board Of Trustees Of The Leland Stanford Junior University | In vivo dna zusammenbau und analyse |
CA3231899A1 (en) | 2021-11-04 | 2023-05-11 | Trevor Stitt | Non-human animals comprising a modified cacng1 locus |
WO2023108047A1 (en) | 2021-12-08 | 2023-06-15 | Regeneron Pharmaceuticals, Inc. | Mutant myocilin disease model and uses thereof |
WO2023122506A1 (en) | 2021-12-20 | 2023-06-29 | Regeneron Pharmaceuticals, Inc. | Non-human animals comprising humanized ace2 and tmprss loci |
WO2023150798A1 (en) | 2022-02-07 | 2023-08-10 | Regeneron Pharmaceuticals, Inc. | Compositions and methods for defining optimal treatment timeframes in lysosomal disease |
WO2023154861A1 (en) | 2022-02-11 | 2023-08-17 | Regeneron Pharmaceuticals, Inc. | Compositions and methods for screening 4r tau targeting agents |
WO2024026488A2 (en) | 2022-07-29 | 2024-02-01 | Regeneron Pharmaceuticals, Inc. | Non-human animals comprising a modified transferrin receptor locus |
WO2024031053A1 (en) | 2022-08-05 | 2024-02-08 | Regeneron Pharmaceuticals, Inc. | Aggregation-resistant variants of tdp-43 |
WO2024073679A1 (en) | 2022-09-29 | 2024-04-04 | Regeneron Pharmaceuticals, Inc. | Correction of hepatosteatosis in humanized liver animals through restoration of il6/il6r/gp130 signaling in human hepatocytes |
Citations (8)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US20030232410A1 (en) * | 2002-03-21 | 2003-12-18 | Monika Liljedahl | Methods and compositions for using zinc finger endonucleases to enhance homologous recombination |
JP2004524841A (ja) * | 2001-02-16 | 2004-08-19 | リジェネロン・ファーマシューティカルズ・インコーポレイテッド | 真核生物細胞を改変する方法 |
JP2007501626A (ja) * | 2003-08-08 | 2007-02-01 | サンガモ バイオサイエンシズ インコーポレイテッド | 標的化された切断及び組換えの方法及び組成物 |
JP2010529042A (ja) * | 2007-06-01 | 2010-08-26 | オーエムティー,インコーポレイティド | 内在性免疫グロブリン遺伝子を阻害し、そして、トランスジェニック・ヒト・イディオタイプ抗体を製造するための組成物及び方法 |
WO2011051390A1 (en) * | 2009-10-28 | 2011-05-05 | Helmholtz Zentrum München - Deutsches Forschungszentrum für Gesundheit und Umwelt (GmbH) | Homologous recombination in the oocyte |
WO2011154927A2 (en) * | 2010-06-10 | 2011-12-15 | Gene Bridges Gmbh | Direct cloning |
WO2012012667A2 (en) * | 2010-07-21 | 2012-01-26 | Sangamo Biosciences, Inc. | Methods and compositions for modification of a hla locus |
WO2012018726A1 (en) * | 2010-08-02 | 2012-02-09 | Cellectis Sa | Method for increasing double-strand break-induced gene targeting |
Family Cites Families (87)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US5830729A (en) | 1996-04-18 | 1998-11-03 | Institut Pasteur | I Sce I-induced gene replacement and gene conversion in embryonic stem cells |
ES2242997T3 (es) | 1997-03-14 | 2005-11-16 | Biogen Idec Inc. | Metodo para integrar genes en sitios especificos en celulas de mamifero por medio de recombinacion homologa y vectores para realizar el mismo. |
US5830698A (en) * | 1997-03-14 | 1998-11-03 | Idec Pharmaceuticals Corporation | Method for integrating genes at specific sites in mammalian cells via homologous recombination and vectors for accomplishing the same |
CA2354542A1 (en) | 1998-12-31 | 2000-07-06 | The J. David Gladstone Institutes | Transgenic rodents and rodent cell lines expressing hiv co-receptors |
EP1147209A2 (en) | 1999-02-03 | 2001-10-24 | The Children's Medical Center Corporation | Gene repair involving the induction of double-stranded dna cleavage at a chromosomal target site |
AU776576B2 (en) * | 1999-12-06 | 2004-09-16 | Sangamo Biosciences, Inc. | Methods of using randomized libraries of zinc finger proteins for the identification of gene function |
US6586251B2 (en) | 2000-10-31 | 2003-07-01 | Regeneron Pharmaceuticals, Inc. | Methods of modifying eukaryotic cells |
US20050144655A1 (en) * | 2000-10-31 | 2005-06-30 | Economides Aris N. | Methods of modifying eukaryotic cells |
US7105348B2 (en) | 2000-10-31 | 2006-09-12 | Regeneron Pharmaceuticals, Inc. | Methods of modifying eukaryotic cells |
US8106255B2 (en) | 2002-01-23 | 2012-01-31 | Dana Carroll | Targeted chromosomal mutagenasis using zinc finger nucleases |
EP1581610A4 (en) | 2002-09-05 | 2009-05-27 | California Inst Of Techn | USE OF CHIMERIC NUCLEASES TO STIMULATE GENE TARGETING |
US20030175968A1 (en) | 2002-10-30 | 2003-09-18 | Golic Kent G. | Gene targeting method |
WO2004063356A2 (en) * | 2003-01-13 | 2004-07-29 | Rao Mahendra S | Persistent expression of candidate molecule in proliferating stem and progenitor cells for delivery of therapeutic products |
US7888121B2 (en) | 2003-08-08 | 2011-02-15 | Sangamo Biosciences, Inc. | Methods and compositions for targeted cleavage and recombination |
US8409861B2 (en) | 2003-08-08 | 2013-04-02 | Sangamo Biosciences, Inc. | Targeted deletion of cellular DNA sequences |
AU2005287278B2 (en) | 2004-09-16 | 2011-08-04 | Sangamo Biosciences, Inc. | Compositions and methods for protein production |
JP5252922B2 (ja) | 2004-10-19 | 2013-07-31 | リジェネロン・ファーマシューティカルズ・インコーポレイテッド | 遺伝的改変についてホモ接合性の動物を生み出すための方法 |
FR2879622B1 (fr) | 2004-12-17 | 2008-02-01 | Agronomique Inst Nat Rech | Procede in vitro de production d'ovocytes ou d'oeufs presentant une modification genomique ciblee |
US10022457B2 (en) | 2005-08-05 | 2018-07-17 | Gholam A. Peyman | Methods to regulate polarization and enhance function of cells |
GB0615327D0 (en) | 2006-03-30 | 2006-09-13 | Univ Edinburgh | Culture medium containing kinase inhibitors and uses thereof |
JP5514539B2 (ja) | 2006-03-31 | 2014-06-04 | メダレックス・リミテッド・ライアビリティ・カンパニー | ヒト抗体の調製に用いるためのキメラ抗体を発現するトランスジェニック動物 |
US7771967B2 (en) | 2006-12-22 | 2010-08-10 | The J. David Gladstone Institutes | Nucleic acid encoding apolipoprotein E-I3 |
US10155038B2 (en) | 2007-02-02 | 2018-12-18 | Yale University | Cells prepared by transient transfection and methods of use thereof |
CA2684378C (en) | 2007-04-26 | 2016-11-29 | Sangamo Biosciences, Inc. | Targeted integration into the ppp1r12c locus |
CA2734235C (en) | 2008-08-22 | 2019-03-26 | Sangamo Biosciences, Inc. | Methods and compositions for targeted single-stranded cleavage and targeted integration |
US20100076057A1 (en) | 2008-09-23 | 2010-03-25 | Northwestern University | TARGET DNA INTERFERENCE WITH crRNA |
EP2180058A1 (en) | 2008-10-23 | 2010-04-28 | Cellectis | Meganuclease recombination system |
WO2010065123A1 (en) | 2008-12-04 | 2010-06-10 | Sangamo Biosciences, Inc. | Genome editing in rats using zinc-finger nucleases |
US20110239315A1 (en) | 2009-01-12 | 2011-09-29 | Ulla Bonas | Modular dna-binding domains and methods of use |
WO2010124200A2 (en) | 2009-04-23 | 2010-10-28 | Transposagen Biopharmaceuticals, Inc. | Genetically modified rat models for cancer |
US8772008B2 (en) | 2009-05-18 | 2014-07-08 | Sangamo Biosciences, Inc. | Methods and compositions for increasing nuclease activity |
WO2011011678A2 (en) | 2009-07-24 | 2011-01-27 | Transposagen Biopharmaceuticals, Inc. | Genetically modified rat models for cytokine-cytokine signaling pathways |
CA2779858C (en) | 2009-10-29 | 2019-10-29 | Aris N. Economides | Multifunctional alleles |
US20120315670A1 (en) | 2009-11-02 | 2012-12-13 | Gen9, Inc. | Compositions and Methods for the Regulation of Multiple Genes of Interest in a Cell |
CA2782596A1 (en) | 2009-12-01 | 2011-06-09 | National Cancer Center | Method for constructing chimeric rat using rat embryonic stem cells |
ES2696825T3 (es) | 2009-12-10 | 2019-01-18 | Univ Minnesota | Modificación del ADN inducida por el efector TAL |
EP2516652B1 (en) | 2009-12-21 | 2014-11-05 | Keygene N.V. | Improved techniques for transfecting protoplasts |
JP2013517774A (ja) | 2010-01-22 | 2013-05-20 | ダウ アグロサイエンシィズ エルエルシー | 遺伝子改変生物における導入遺伝子の切除 |
CA2788850C (en) * | 2010-02-09 | 2019-06-25 | Sangamo Biosciences, Inc. | Targeted genomic modification with partially single-stranded donor molecules |
CA2798988C (en) | 2010-05-17 | 2020-03-10 | Sangamo Biosciences, Inc. | Tal-effector (tale) dna-binding polypeptides and uses thereof |
CN104711218B (zh) | 2010-06-11 | 2018-09-25 | 瑞泽恩制药公司 | 由xy es细胞制备能育的xy雌性动物 |
WO2012129198A1 (en) | 2011-03-23 | 2012-09-27 | Transposagen Biopharmaceuticals, Inc. | Genetically modified rat models for obesity and diabetes |
US20140304847A1 (en) | 2011-06-07 | 2014-10-09 | Ralf Kühn | Recombination efficiency by inhibition of nhej dna repair |
CN107858332A (zh) | 2011-10-28 | 2018-03-30 | 瑞泽恩制药公司 | T细胞受体基因修饰小鼠 |
US9637739B2 (en) | 2012-03-20 | 2017-05-02 | Vilnius University | RNA-directed DNA cleavage by the Cas9-crRNA complex |
WO2013141680A1 (en) | 2012-03-20 | 2013-09-26 | Vilnius University | RNA-DIRECTED DNA CLEAVAGE BY THE Cas9-crRNA COMPLEX |
IN2014DN09261A (ja) | 2012-04-25 | 2015-07-10 | Regeneron Pharma | |
BR112014027813A2 (pt) | 2012-05-07 | 2017-08-08 | Dow Agrosciences Llc | métodos e composições para integração de transgenes direcionada mediada por nuclease |
EP4289948A3 (en) | 2012-05-25 | 2024-04-17 | The Regents of the University of California | Methods and compositions for rna-directed target dna modification and for rna-directed modulation of transcription |
JP6279562B2 (ja) | 2012-06-12 | 2018-02-14 | ジェネンテック, インコーポレイテッド | 条件付きノックアウト対立遺伝子を生成するための方法および組成物 |
WO2014018423A2 (en) | 2012-07-25 | 2014-01-30 | The Broad Institute, Inc. | Inducible dna binding proteins and genome perturbation tools and applications thereof |
JP6517143B2 (ja) | 2012-10-23 | 2019-05-22 | ツールゲン インコーポレイテッド | 標的dnaに特異的なガイドrnaおよびcasタンパク質コード核酸またはcasタンパク質を含む、標的dnaを切断するための組成物、ならびにその使用 |
US20160017366A1 (en) | 2012-12-06 | 2016-01-21 | Sigma-Aldrich Co. Llc | Crispr-based genome modification and regulation |
WO2014093479A1 (en) | 2012-12-11 | 2014-06-19 | Montana State University | Crispr (clustered regularly interspaced short palindromic repeats) rna-guided control of gene regulation |
EP2931899A1 (en) | 2012-12-12 | 2015-10-21 | The Broad Institute, Inc. | Functional genomics using crispr-cas systems, compositions, methods, knock out libraries and applications thereof |
EP2931892B1 (en) | 2012-12-12 | 2018-09-12 | The Broad Institute, Inc. | Methods, models, systems, and apparatus for identifying target sequences for cas enzymes or crispr-cas systems for target sequences and conveying results thereof |
PL2784162T3 (pl) | 2012-12-12 | 2016-01-29 | Broad Inst Inc | Opracowanie systemów, metod oraz zoptymalizowanych kompozycji przewodnikowych do manipulacji sekwencyjnej |
US20140310830A1 (en) | 2012-12-12 | 2014-10-16 | Feng Zhang | CRISPR-Cas Nickase Systems, Methods And Compositions For Sequence Manipulation in Eukaryotes |
US8697359B1 (en) | 2012-12-12 | 2014-04-15 | The Broad Institute, Inc. | CRISPR-Cas systems and methods for altering expression of gene products |
US20140189896A1 (en) | 2012-12-12 | 2014-07-03 | Feng Zhang | Crispr-cas component systems, methods and compositions for sequence manipulation |
ES2786193T3 (es) | 2012-12-12 | 2020-10-09 | Broad Inst Inc | Modificación por tecnología genética y optimización de sistemas, métodos y composiciones enzimáticas mejorados para la manipulación de secuencias |
WO2014093655A2 (en) | 2012-12-12 | 2014-06-19 | The Broad Institute, Inc. | Engineering and optimization of systems, methods and compositions for sequence manipulation with functional domains |
PL2921557T3 (pl) | 2012-12-12 | 2017-03-31 | Broad Inst Inc | Projektowanie systemów, sposoby i optymalizowane kompozycje kierujące do manipulacji sekwencją |
US20140179770A1 (en) | 2012-12-12 | 2014-06-26 | Massachusetts Institute Of Technology | Delivery, engineering and optimization of systems, methods and compositions for sequence manipulation and therapeutic applications |
KR20150095861A (ko) | 2012-12-17 | 2015-08-21 | 프레지던트 앤드 펠로우즈 오브 하바드 칼리지 | Rna-가이드된 인간 게놈 조작 |
CN105025701B (zh) | 2012-12-27 | 2018-09-25 | 凯津公司 | 去除植物中遗传连锁的方法 |
WO2014127287A1 (en) | 2013-02-14 | 2014-08-21 | Massachusetts Institute Of Technology | Method for in vivo tergated mutagenesis |
BR112015019950B1 (pt) | 2013-02-20 | 2023-02-14 | Regeneron Pharmaceuticals, Inc | Método para gerar linhagem de células-tronco embrionárias (es) de rato, e, cultura in vitro |
WO2014130955A1 (en) | 2013-02-25 | 2014-08-28 | Sangamo Biosciences, Inc. | Methods and compositions for enhancing nuclease-mediated gene disruption |
JP2016507244A (ja) | 2013-02-27 | 2016-03-10 | ヘルムホルツ・ツェントルム・ミュンヒェン・ドイチェス・フォルシュンクスツェントルム・フューア・ゲズントハイト・ウント・ウムベルト(ゲーエムベーハー)Helmholtz Zentrum MuenchenDeutsches Forschungszentrum fuer Gesundheit und Umwelt (GmbH) | Cas9ヌクレアーゼによる卵母細胞における遺伝子編集 |
US10612043B2 (en) | 2013-03-09 | 2020-04-07 | Agilent Technologies, Inc. | Methods of in vivo engineering of large sequences using multiple CRISPR/cas selections of recombineering events |
EP3620534B1 (en) | 2013-03-14 | 2021-10-13 | Caribou Biosciences, Inc. | Crispr-cas compositions of nucleic acid-targeting nucleic acids |
US9234213B2 (en) | 2013-03-15 | 2016-01-12 | System Biosciences, Llc | Compositions and methods directed to CRISPR/Cas genomic engineering systems |
US20140273230A1 (en) | 2013-03-15 | 2014-09-18 | Sigma-Aldrich Co., Llc | Crispr-based genome modification and regulation |
US20140349400A1 (en) | 2013-03-15 | 2014-11-27 | Massachusetts Institute Of Technology | Programmable Modification of DNA |
JP6346266B2 (ja) | 2013-03-21 | 2018-06-20 | サンガモ セラピューティクス, インコーポレイテッド | 操作されたジンクフィンガータンパク質ヌクレアーゼを使用するt細胞受容体遺伝子の標的化された破壊 |
WO2014165825A2 (en) | 2013-04-04 | 2014-10-09 | President And Fellows Of Harvard College | Therapeutic uses of genome editing with crispr/cas systems |
US20160186208A1 (en) | 2013-04-16 | 2016-06-30 | Whitehead Institute For Biomedical Research | Methods of Mutating, Modifying or Modulating Nucleic Acid in a Cell or Nonhuman Mammal |
HUE040575T2 (hu) | 2013-04-16 | 2019-03-28 | Regeneron Pharma | A patkány genom célzott módosítása |
WO2014172458A1 (en) | 2013-04-16 | 2014-10-23 | University Of Washington Through Its Center For Commercialization | Activating an alternative pathway for homology-directed repair to stimulate targeted gene correction and genome engineering |
EP2796558A1 (en) | 2013-04-23 | 2014-10-29 | Rheinische Friedrich-Wilhelms-Universität Bonn | Improved gene targeting and nucleic acid carrier molecule, in particular for use in plants |
US11306328B2 (en) | 2013-07-26 | 2022-04-19 | President And Fellows Of Harvard College | Genome engineering |
AU2014360811B2 (en) | 2013-12-11 | 2017-05-18 | Regeneron Pharmaceuticals, Inc. | Methods and compositions for the targeted modification of a genome |
HUE049776T2 (hu) | 2014-06-06 | 2020-10-28 | Regeneron Pharma | Módszerek és készítmények egy célzott lókusz módosítására |
ES2901074T3 (es) | 2014-06-26 | 2022-03-21 | Regeneron Pharma | Métodos y composiciones para modificaciones genéticas objetivo y métodos de uso |
EP3169773B1 (en) | 2014-07-15 | 2023-07-12 | Juno Therapeutics, Inc. | Engineered cells for adoptive cell therapy |
AU2015364427B2 (en) | 2014-12-19 | 2021-05-27 | Regeneron Pharmaceuticals, Inc. | Methods and compositions for targeted genetic modification through single-step multiple targeting |
-
2013
- 2013-04-25 IN IN9261DEN2014 patent/IN2014DN09261A/en unknown
- 2013-04-25 SG SG11201406547YA patent/SG11201406547YA/en unknown
- 2013-04-25 PT PT137207189T patent/PT2847335T/pt unknown
- 2013-04-25 BR BR112014026294-2A patent/BR112014026294B1/pt active IP Right Grant
- 2013-04-25 CN CN201380030738.6A patent/CN104364380B/zh active Active
- 2013-04-25 JP JP2015509128A patent/JP6275120B2/ja active Active
- 2013-04-25 EP EP13720718.9A patent/EP2847335B1/en active Active
- 2013-04-25 SG SG10201702445TA patent/SG10201702445TA/en unknown
- 2013-04-25 WO PCT/US2013/038165 patent/WO2013163394A1/en active Application Filing
- 2013-04-25 KR KR1020147030262A patent/KR101904508B1/ko active IP Right Grant
- 2013-04-25 CA CA2869016A patent/CA2869016C/en active Active
- 2013-04-25 AU AU2013251558A patent/AU2013251558B2/en active Active
- 2013-04-25 MX MX2014012994A patent/MX362523B/es active IP Right Grant
- 2013-04-25 ES ES13720718.9T patent/ES2683071T3/es active Active
- 2013-04-25 PL PL13720718T patent/PL2847335T3/pl unknown
- 2013-04-25 DK DK13720718.9T patent/DK2847335T3/en active
- 2013-04-25 US US13/870,280 patent/US9834786B2/en active Active
- 2013-04-25 CN CN201811024942.8A patent/CN109536526B/zh active Active
- 2013-04-25 RU RU2014145942A patent/RU2645475C2/ru active
-
2014
- 2014-09-30 IL IL234905A patent/IL234905B/en active IP Right Grant
-
2015
- 2015-08-24 HK HK15108155.7A patent/HK1207396A1/xx unknown
-
2017
- 2017-10-24 US US15/792,112 patent/US10301646B2/en active Active
-
2018
- 2018-08-06 CY CY20181100810T patent/CY1120572T1/el unknown
Patent Citations (8)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
JP2004524841A (ja) * | 2001-02-16 | 2004-08-19 | リジェネロン・ファーマシューティカルズ・インコーポレイテッド | 真核生物細胞を改変する方法 |
US20030232410A1 (en) * | 2002-03-21 | 2003-12-18 | Monika Liljedahl | Methods and compositions for using zinc finger endonucleases to enhance homologous recombination |
JP2007501626A (ja) * | 2003-08-08 | 2007-02-01 | サンガモ バイオサイエンシズ インコーポレイテッド | 標的化された切断及び組換えの方法及び組成物 |
JP2010529042A (ja) * | 2007-06-01 | 2010-08-26 | オーエムティー,インコーポレイティド | 内在性免疫グロブリン遺伝子を阻害し、そして、トランスジェニック・ヒト・イディオタイプ抗体を製造するための組成物及び方法 |
WO2011051390A1 (en) * | 2009-10-28 | 2011-05-05 | Helmholtz Zentrum München - Deutsches Forschungszentrum für Gesundheit und Umwelt (GmbH) | Homologous recombination in the oocyte |
WO2011154927A2 (en) * | 2010-06-10 | 2011-12-15 | Gene Bridges Gmbh | Direct cloning |
WO2012012667A2 (en) * | 2010-07-21 | 2012-01-26 | Sangamo Biosciences, Inc. | Methods and compositions for modification of a hla locus |
WO2012018726A1 (en) * | 2010-08-02 | 2012-02-09 | Cellectis Sa | Method for increasing double-strand break-induced gene targeting |
Non-Patent Citations (1)
Title |
---|
NATURE BIOTECHNOLOGY, vol. 25, no. 11, JPN6016050836, 2007, pages 1298 - 1306, ISSN: 0003711154 * |
Also Published As
Similar Documents
Publication | Publication Date | Title |
---|---|---|
US10301646B2 (en) | Nuclease-mediated targeting with large targeting vectors | |
JP7154248B2 (ja) | 標的遺伝子座を修飾するための方法及び組成物 | |
KR102530821B1 (ko) | 단일 단계 다중 표적화를 통한 표적화된 유전자 변형을 위한 방법 및 조성물 | |
Young et al. | Genome editing in mice using CRISPR/Cas |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
A521 | Request for written amendment filed |
Free format text: JAPANESE INTERMEDIATE CODE: A523 Effective date: 20160406 |
|
A621 | Written request for application examination |
Free format text: JAPANESE INTERMEDIATE CODE: A621 Effective date: 20160406 |
|
A131 | Notification of reasons for refusal |
Free format text: JAPANESE INTERMEDIATE CODE: A131 Effective date: 20170105 |
|
A521 | Request for written amendment filed |
Free format text: JAPANESE INTERMEDIATE CODE: A523 Effective date: 20170404 |
|
A521 | Request for written amendment filed |
Free format text: JAPANESE INTERMEDIATE CODE: A821 Effective date: 20170404 |
|
A131 | Notification of reasons for refusal |
Free format text: JAPANESE INTERMEDIATE CODE: A131 Effective date: 20170908 |
|
A521 | Request for written amendment filed |
Free format text: JAPANESE INTERMEDIATE CODE: A523 Effective date: 20171201 |
|
TRDD | Decision of grant or rejection written | ||
A01 | Written decision to grant a patent or to grant a registration (utility model) |
Free format text: JAPANESE INTERMEDIATE CODE: A01 Effective date: 20171228 |
|
A61 | First payment of annual fees (during grant procedure) |
Free format text: JAPANESE INTERMEDIATE CODE: A61 Effective date: 20180109 |
|
R150 | Certificate of patent or registration of utility model |
Ref document number: 6275120 Country of ref document: JP Free format text: JAPANESE INTERMEDIATE CODE: R150 |
|
R250 | Receipt of annual fees |
Free format text: JAPANESE INTERMEDIATE CODE: R250 |
|
R250 | Receipt of annual fees |
Free format text: JAPANESE INTERMEDIATE CODE: R250 |
|
R250 | Receipt of annual fees |
Free format text: JAPANESE INTERMEDIATE CODE: R250 |
|
R250 | Receipt of annual fees |
Free format text: JAPANESE INTERMEDIATE CODE: R250 |